TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06465433: An Open-Label, Multicenter, Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab

Sponsor: Incyte Corporation · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 25 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,652,800

Rescue Site Savings

+$4,389,000

Unlock Full NCT06465433 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06465433 Rescue Dossier →